The radial compression devices market is valued at USD 398.4 million in 2021 and is poised to grow at a significant CAGR of 7.6% over 2022–2028. Dial artery access is a development in contemporary interventional cardiology for cardiovascular testing and intervention. The smaller size of the artery and an easier position for safe compression with a decreased risk of severe access site haemorrhage, which may have a detrimental effect on prognosis, are the key benefits of using the radial artery. Since it has shown that routinely using radial artery access can lower both access site haemorrhage and overall mortality, particularly when combined with the concurrent use of strong antithrombotic drugs. Radial access issues are uncommon due to the superficial position and simplicity of compression, making access site maintenance following intervention simpler than with femoral access.
Recent Market Developments:
In Aug 2019, PreludeSYNC EVO, a radial compression device, was introduced in the US by Merit Medical. Following catheterization procedures, this sterile, one-time-use device helps to achieve hemostasis at the artery percutaneous access site.